John Greene

Track

Insider profile

Currently holds positions in Discover Financial Services, Bioverativ Inc and CRISPR Therapeutics AG

Performance

Overall performance
2.7
Performance over holding periods
4.2
30 days 90 days 120 days
Average return -1% 8.2% 15.1%
Success rate 50% 68% 82%
Transactions
3 67% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 82%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Chief Financial Officer, Executive Vice President Discover Financial Services Sept. 18, 2019 -
Chief Financial Officer, Executive Vice President, Treasurer Bioverativ Inc Nov. 7, 2016 -
Independent Director CRISPR Therapeutics AG June 11, 2019 -
Group Chief Financial Officer Willis Towers Watson Public Limited Company June 2, 2014 - Jan. 4, 2016
John Greene's trades of CRISPR Therapeutics AG's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
202.58
Quantity 3,308
Value US$2,288,814
Transaction date
Purchase
Price
73.84
Quantity 3,377 +14.0%
Value US$249,343
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-02-28 2025-02-26
B Purchase
63,604 -21.0%
308.38
US$2,646,496 		63,604 -21.0% 308.38 US$2,646,496
2024-01-30 2024-01-26
PlS Planned sale
68,113 +30.6%
412.33
US$4,088,278 		68,113 +30.6% 412.33 US$4,088,278
2024-01-26 2024-01-26
PrS Proposed sale
3,308
202.58
US$2,288,814 		3,308 202.58 US$2,288,814
2022-02-17 2022-02-15
S Sale
4,443 -14.3%
127.95
US$568,464 		4,443 -14.3% 127.95 US$568,464
2020-01-27 2020-01-27
B Purchase
3,377 +14.0%
73.84
US$249,343 		3,377 +14.0% 73.84 US$249,343